TapImmune to Open New Laboratories and Offices in Seattle’s Newest Biotech Hub
News Jan 19, 2012
The sublease was signed with Puget Sound Blood Center Research Institute and includes a service agreement enabling TapImmune's scientific research team to access a wide array of functioning core labs and shared equipment in an innovative and cooperative model for scientific research and development. TapImmune will move into the facility on January, 23, 2012.
"We are very excited to be working with the Puget Sound Blood Center's internationally-recognized group of scientific investigators since this allows a leveraging of our development dollars in a way that expands our capabilities well beyond our core staff," said Mark Reddish, TapImmune's Vice President of Product Development. "The labs include equipment and expertise that we would not otherwise be able to access as a start-up operation. Having access to Mass Spectrometry, Fluorescent Activated Cell Sorting (FACS) as well as a DNA sequencing lab affords our new team of scientists the opportunity to immediately begin delivery of our gene based product candidates for clinical trials."
"It has been a pleasure working with the leadership team at the Research Institute, and we look forward to a dynamic research environment in this new medical/biotechnology hub," noted Chairman and CEO, Dr. Glynn Wilson, "This represents an important corporate milestone in advancing the clinical development of TapImmune's immunotherapy products and supporting of our external research and development collaborations."
Jim Gore, chief operating officer of Puget Sound Blood Center Research Institute, was responsible for the design and renovations of the new facility. "We're delighted to be welcoming TapImmune's research and development team into the facility, and the synergy it will create with our own scientific teams," Gore said. "We believe that our unique approach of creating 'scientific cooperative' by sharing of core support delivers significant benefits to researchers from both organizations in their complementary areas of investigation."
The 1551 Eastlake facility -- owned and operated by Alexandria Real Estate Equities -- has become a new Seattle hub for biomedical research, including the Puget Sound Blood Center, the Washington Biotechnology and Biomedical Association and the Life Sciences Discovery Fund, among others. The facility was previously the headquarters of the Bill & Melinda Gates Foundation.
With their ability to treat a wide a variety of diseases, spherical nucleic acids are poised to revolutionize medicine. But before these digitally designed nanostructures can reach their full potential, researchers need to optimize their various components. A team has developed a direct route to optimize these particles, bringing them one step closer to becoming a viable treatment option for numerous diseases, including cancer.READ MORE
15th International Conference on Surgical Pathology and Cancer Diagnosis
Apr 15 - Apr 16, 2019